Previous 10 | Next 10 |
home / stock / mgnx / mgnx articles
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling around 0.2% points on Friday. The Dow traded up 0.12% to 39,516....
On Thursday, MacroGenics Inc (NASDAQ:MGNX) released interim data from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) that ...
LOS ANGELES, May 10, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investiga...
Shares of Natera, Inc. (NASDAQ:NTRA) rose sharply in today's pre-market trading following strong first-quarter earnings. Natera posted GAAP lo...
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday. Shares of Akamai Technologies, Inc. (NASDAQ:...
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on developing, manufactur...
Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see an 82% surge. The rev...
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-qua...
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday. Shares of Simulations Plus, Inc. (NASDA...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, July 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...
MacroGenics, Inc. (NASDAQ: MGNX) is the focus of IBN's latest stock spotlight. The company's shares have moved 1.07% on the day to $4.7. MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved pr...
SAN FRANCISCO, July 03, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916...